MedTrace Logo

Registry of Sustained Immunity to COVID-19 Among ESKD Patients

NCT04495764 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2315

Last updated 2021-05-27

No results posted yet for this study

Summary

This is a multi-center, prospective registry study of subjects undergoing hemodialysis for treatment of end-stage renal disease in a DaVita center.

The objective of this study is to understand whether and to what degree anti-SARS-CoV-2 antibodies mitigate the risk of subsequent SARS-CoV-2 infection and COVID disease within the ESKD population.

Conditions

Sponsors & Collaborators

  • Davita Clinical Research

    lead INDUSTRY

Principal Investigators

  • Francesca Tentori, MD · Davita Clinical Research

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-20
Primary Completion
2021-02-12
Completion
2021-02-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04495764 on ClinicalTrials.gov